PHLDA3: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: PHLDA3

NCBI ID: G23612

PHLDA3

PHLDA3: A Potential Drug Target Or Biomarker for Various Diseases

PHLDA3 (Promyelocytic leukemia like disease 3) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including leukemia, lymphoma, and melanoma. The PHLDA3 gene is a member of the PHLDA gene family, which is known for its role in the development and progression of leukemia.

The PHLDA3 gene has been shown to be aberrantly expressed in various types of leukemia, including acute myeloid leukemia, chronic myeloid leukemia, and blastic plasmacytois leukemia. In addition, the PHLDA3 gene has also been shown to be involved in the development and progression of lymphoma, including Hodgkin lymphoma and non-Hodgkin lymphoma.

One of the key challenges in the treatment of leukemia is the development of resistance to chemotherapy, which can limit the effectiveness of treatment and increase the risk of relapse. Researchers have been interested in using PHLDA3 as a potential drug target or biomarker to overcome this challenge.

One approach to using PHLDA3 as a drug target is to target the PHLDA3 gene directly with small molecules or antibodies. This can involve using drugs that bind to specific regions of the PHLDA3 gene, such as the gene's cytoplasmic domain or the N-terminus. By blocking the function of the PHLDA3 gene, researchers hope to reduce the production of leukemia cells and potentially slow down or stop the progression of leukemia.

Another approach to using PHLDA3 as a drug target is to use it as a biomarker to predict the risk of relapse. By analyzing the levels of PHLDA3 in leukemia cells, researchers can determine whether a patient is at risk of relapse and target their treatment accordingly. This approach has the potential to improve the accuracy of relapse predictions and increase the effectiveness of targeted treatments.

In addition to its potential as a drug target or biomarker, PHLDA3 is also of interest as a potential therapeutic target for other diseases. For example, the PHLDA3 gene has been shown to be involved in the development and progression of various types of cancer, including melanoma. Therefore, researchers are interested in using PHLDA3 as a potential drug target or biomarker for the treatment of melanoma and other skin cancers.

Overall, the PHLDA3 gene has the potential to be a valuable drug target or biomarker for the treatment of various diseases, including leukemia, lymphoma, and melanoma. Further research is needed to fully understand its function and develop effective treatments.

Protein Name: Pleckstrin Homology Like Domain Family A Member 3

Functions: p53/TP53-regulated repressor of Akt/AKT1 signaling. Represses AKT1 by preventing AKT1-binding to membrane lipids, thereby inhibiting AKT1 translocation to the cellular membrane and activation. Contributes to p53/TP53-dependent apoptosis by repressing AKT1 activity. Its direct transcription regulation by p53/TP53 may explain how p53/TP53 can negatively regulate AKT1. May act as a tumor suppressor

The "PHLDA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHLDA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets